<DOC>
	<DOCNO>NCT02296281</DOCNO>
	<brief_summary>The purpose study assess safety efficacy pirfenidone capsule treat grade 2 radiation-induced lung injury patient .</brief_summary>
	<brief_title>Safety Efficacy Study Pirfenidone Treat Grade 2 Above Radiation-induced Lung Injury</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Radiation Pneumonitis</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>1 . 1870 year old ( include 18 70 year ) , male female 2 . The pathological diagnosis lung cancer , nonsmall cell lung cancer ( NSCLC ) stag IIIA IIIB , small cell lung cancer ( SCLC ) council deadline 3 . General condition assessment , ECOG score 01 4 . Enough heart , liver kidney function , AST , ALT , LDH≤2 time ULN plasma total bilirubin , creatinine ≤1.5 time ULN ; hematopoietic function enough , neutrophil ≥4.0 x109 / L , platelets ≥100 x109 / L 5 . The expected survival 6 month 6 . Subject able eat solid food 7 . The initial radical thoracic radiotherapy treatment 8 . The clinical diagnosis radiationinduced lung injury Grade 2 9 . The duration radiationinduced lung injury le 1 month 10 . Signed informed consent 1 . Radiationinduced lung injury enter chronic phase 2 . A history chronic bronchitis , emphysema , history cor pulmonale 3 . Lung resection surgery 4 . Cancer progression 5 . Pulmonary infection 6 . Associated serious disease : occur within 6 month myocardial infarction , uncontrolled diabetes etc . 7 . With active peptic ulcer 8 . Pregnant woman patient mental disease 9 . Those participate clinical trial drug within 3 month 10 . Investigator judge apply participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>